Parabolic Drugs Q1, Q2, Q3, Q4, FY 2017-18, FY 2016-17 Standalone / Consolidated Results, Revenues, Net Profit, Tax, EPS, Live Chart …

Parabolic Drugs Company Profile :

Parabolic Drugs Limited is an Indian company engaged in the business of development and manufacturing of Active Pharmaceutical Ingredients (API) and API intermediates.

Company is engaged in the manufacture of pharmaceuticals, medicinal chemical and botanical products.

Company products and services include Cefuroxime Axetil Amorphus and Ceftriaxone Sodium Sterile. Its product portfolio includes Oral and Sterile Semi Synthetic Penicillin API, Oral and Sterile Cephalosporin API in antibiotic segment to non-antibiotic API in the Cardiovascular, Nonsteroidal anti-inflammatory drugs (NSAID), Anti-Hypertensive and Osteoporosis segments.


Parabolic Drugs ResultsBSE Code : 533211
NSE Symbol : PARABDRUGS
ISIN No. : INE618H01016
Industry : Pharmaceuticals
Face Value : Rs. 10.00


If you are an investor who has shares of Parabolic Drugs or you are an stock market analyst then i am sure you might for Quarterly Results of Parabolic Drugs.

In this article you will find Q1, Q2, Q3, Q4 and FY 2017-18 Results of Parabolic Drugs. That’s not all, you can compare those results with previous year i.e., FY 2016-17 Results of Parabolic Drugs.

Parabolic Drugs Q1 Results 2017-18 :

Parabolic Drugs will announce its Q1 FY 2017-18 Results in August 2017. Will soon update the below mentioned table.

(Values in Cr.) Q1 Standalone Q1 Consolidated
Revenue
Other Income
Total Income
Expenditure
Interest
Depreciation
PBT
Tax
Net Profit
Equity
EPS

Parabolic Drugs will announce its Q2 FY 2017-18 Results in the month of October 2017.

(Values in Cr.) Q2 Standalone Q2 Consolidated
Revenue
Other Income
Total Income
Expenditure
Interest
Depreciation
PBT
Tax
Net Profit
Equity
EPS

Parabolic Drugs will announce its Q3 FY 2017-18 Results in the month of January 2018.

(Values in Cr.) Q3 Standalone Q3 Consolidated
Revenue
Other Income
Total Income
Expenditure
Interest
Depreciation
PBT
Tax
Net Profit
Equity
EPS

Parabolic Drugs will announce its Q4 FY 2017-18 Results in the month of April 2018.

(Values in Cr.) Q4 Standalone Q4 Consolidated
Revenue
Other Income
Total Income
Expenditure
Interest
Depreciation
PBT
Tax
Net Profit
Equity
EPS

Parabolic Drugs will announce its FY 2017-18 Results in the month of April 2018.

(Values in Cr.) FY 2017-18 Standalone FY 2017-18 Consolidated
Revenue
Other Income
Total Income
Expenditure
Interest
Depreciation
PBT
Tax
Net Profit
Equity
EPS

Note : We will update the results table above as and when results are announced. Visit again.

Parabolic Drugs Previous Year’s Results (FY 2016-17) :

(Values in Cr.) FY 2016-17 Standalone FY 2016-17 Consolidated
Revenue
Other Income
Total Income
Expenditure
Interest
Depreciation
PBT
Tax
Net Profit
Equity
EPS

Note : If you like this information about Parabolic Drugs Quarterly Results, then please share it with all your friends, relatives and other investors on Facebook, Twitter, WhatsApp, Email, etc.